Echosens

Focus: Echosens is a Paris-based diagnostics company specializing in live diagnostic technologies and data management software, with a core focus on non-invasive liver disease assessment via its FibroScan platform.

Unknown

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About Echosens

AI assessmentNot Hiring

No open roles listed right now. Follow Echosens to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

21 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Key Products

FibroScan

Liver Fibrosis, Cirrhosis, NAFLD, NASH, Chronic Liver Disease

Peak

Flagship non-invasive transient elastography device with CE mark approval, deployed across 20+ clinical studies in liver disease stratification.

FibroScan 530 Compact

Chronic Liver Disease

Help build intelligence for Echosens

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Established flagship product (FibroScan) with 20 active clinical trials spanning liver disease, NASH, cirrhosis, and emerging indications like heart failure
European headquarters offers access to diverse regulatory pathways (CE mark, EMA) and strong hepatology research ecosystem
Expanding diagnostic portfolio beyond liver (Cutometer for venous insufficiency, HIV diagnostic) signals product diversification strategy

Watch Out For

Only 2 active job openings (both marketing-focused) suggest minimal hiring momentum and limited internal mobility
No disclosed revenue, funding stage, employee count, or R&D spend limits visibility into financial stability and growth trajectory
All pipeline programs in observational/research phases with no formal drug development pipeline, indicating diagnostics-only business model without therapeutic expansion

Generated by Claude from Echosens's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Compact iteration of core platform targeting wider clinical adoption and patient access in resource-limited settings.

FibroScan 630 Research Model

Obesity, Morbid

Growth

Extended probe technology addressing obese populations with severe adipose tissue, expanding addressable market beyond standard BMI ranges.

Cutometer

Venous Insufficiency

Growth

Secondary product line indicating early portfolio diversification beyond hepatology into dermatological and vascular assessment.

Pipeline & Clinical Trials

Fibroscan® examination

Cirrhosis

N/A

Clinical Trials (1)

NCT02180113Spleen Stiffness Measurement With FibroScan

N/A

FibroScan

Non-Alcoholic Fatty Liver Disease

N/A

Clinical Trials (1)

NCT06877026FibroScan-Reproducibility and Repeatability Study

N/A

VCTE with splenic stiffness measurement

Advanced Chronic Liver Disease, NASH

N/A

Clinical Trials (1)

NCT03778411Non-invasive Evaluation of Portal Hypertension in Patients With Compensated Advanced Chronic Liver Disease by Assessment of Spleen Stiffness Using VCTE by FibroScan.

N/A

FibroScan® examination.

Non-alcoholic Fatty Liver Disease

N/A

Clinical Trials (1)

NCT01985009Prospective, Cross-sectional and Multicenter Study, Evaluating the Diagnosis Accuracy of the Controlled Attenuation Parameter(CAP) Measured by FibroScan® (Either With M+ or XL+ Probe) in Patient With Non-Alcoholic Fatty Liver Disease Using Liver Biopsy as Reference.

N/A

FibroScan

Cirrhosis

N/A

Clinical Trials (1)

NCT00125762FibroScan in Patients With Hepatitis B and C Presenting for Liver Biopsy

N/A

Global Research Initiative for Patients Screening on MASH

MASH

N/A

Evaluation of the Diagnostic of Hepatic Fibrosis With the XL Probe of the Fibroscan Versus Biopsies in Severe Obese Patients Candidates to Bariatric Surgery

Steatosis

N/A

Clinical Trials (1)

NCT03548597Evaluation of the Diagnostic of Hepatic Fibrosis With the in Severe Obese Patients Candidates to Bariatric Surgery

N/A

Research FibroScan

Liver Fibrosis

N/A

Clinical Trials (1)

NCT04747457Development of Predictive Indicators of Homogeneous Propagation of Ultrasound and Elastic Waves During VCTE Examination

N/A

Research FibroScan